Phase II trial of Hsp-E7 (SGN-00101 [verpasep caltespen]) in women with high grade cervical dysplasia

Trial Profile

Phase II trial of Hsp-E7 (SGN-00101 [verpasep caltespen]) in women with high grade cervical dysplasia

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2006

At a glance

  • Drugs Verpasep caltespen (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top